ONCONANO MEDICINE: GILEAD HAS OPTION TO EXPAND DEAL BY NOMINATING ADDITIONAL TARGET FOR ON-BOARD TECHNOLOGY, IN WHICH CO WOULD RECEIVE UP TO $300 MLN

Reuters · 5d ago

Please log in to view news